| scholarly article | Q13442814 |
| P50 | author | Ana M Bertoli | Q46756447 |
| Graciela S Alarcón | Q67485107 | ||
| John D Reveille | Q67485113 | ||
| Jaime Calvo-Alén | Q91866349 | ||
| Barri J Fessler | Q114433878 | ||
| LUMINA Study Group | Q114722503 | ||
| Holly M Bastian | Q114722504 | ||
| P2093 | author name string | Gerald McGwin | |
| Luis M Vilá | |||
| P2860 | cites work | Discontinuation of antimalarial drugs in systemic lupus erythematosus | Q28374806 |
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Antimalarials--the 'real' advance in lupus | Q34297582 | ||
| Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group | Q39605645 | ||
| Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. | Q41109148 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology | Q41917354 | ||
| A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group | Q41926859 | ||
| A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | Q41942545 | ||
| Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis | Q41944990 | ||
| Divergent racial trends in mortality from systemic lupus erythematosus | Q42623872 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group | Q43589680 | ||
| How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? | Q43882941 | ||
| Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes | Q43970492 | ||
| Infections in patients with rheumatoid arthritis treated with biologic agents | Q44952372 | ||
| Reduction of sampling bias of odds ratios for vertebral fractures using propensity scores | Q46107913 | ||
| Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual | Q46223662 | ||
| Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture | Q46430510 | ||
| Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). | Q46490126 | ||
| Morbidity of systemic lupus erythematosus: role of race and socioeconomic status | Q46891297 | ||
| Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage | Q47684491 | ||
| Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study | Q57751439 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXXI: factors associated with patients being lost to follow-up | Q61811942 | ||
| The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus | Q73013000 | ||
| The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison | Q73471436 | ||
| High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus | Q74508440 | ||
| The effects of ethnicity on disease patterns in 472 Orientals with systemic lupus erythematosus | Q74805339 | ||
| The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing | Q78794804 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| patient | Q181600 | ||
| lupus erythematosus | Q188297 | ||
| hydroxychloroquine | Q421094 | ||
| multiethnicity | Q111242702 | ||
| P304 | page(s) | 1168-1172 | |
| P577 | publication date | 2007-03-27 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | |
| P478 | volume | 66 |
| Q38352048 | A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. |
| Q41926759 | A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus |
| Q51702281 | A study of Thai patients with systemic lupus erythematosus in the medical intensive care unit: epidemiology and predictors of mortality. |
| Q36746012 | Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions |
| Q92737146 | An audit of the use of hydroxychloroquine in rheumatology clinics |
| Q47967726 | Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period |
| Q41680597 | Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus |
| Q34044918 | Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort |
| Q38903851 | Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. |
| Q41919852 | Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. |
| Q41939554 | Antimalarials. A treatment option for every lupus patient!? |
| Q36573884 | Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort |
| Q38365624 | Atherosclerotic vascular disease in the autoimmune rheumatologic patient |
| Q34338929 | Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus |
| Q104559093 | COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease |
| Q98620978 | Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases? |
| Q37330468 | Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q38554636 | Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review |
| Q51299667 | Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. |
| Q41918308 | Chloroquine and Hydroxychloroquine Increase Retinal Pigment Epithelial Layer Permeability. |
| Q92006099 | Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE |
| Q47096234 | Complement levels and risk of organ involvement in patients with systemic lupus erythematosus |
| Q47441501 | Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus. |
| Q36152835 | Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences |
| Q26741266 | Current and emerging treatment options in the management of lupus |
| Q41923517 | Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis |
| Q33422958 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus |
| Q38776952 | Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood |
| Q47790587 | Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus |
| Q34161393 | Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort |
| Q50222848 | Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort |
| Q41913718 | Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial |
| Q28265144 | Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha |
| Q37883018 | Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. |
| Q53839415 | Epidemiology of systemic lupus erythematosus. |
| Q43427893 | Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus |
| Q41922310 | Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study |
| Q92026856 | Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues |
| Q41914711 | Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus |
| Q64924819 | First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatolog |
| Q24613829 | Healthcare quality in systemic lupus erythematosus: using Donabedian’s conceptual framework to understand what we know |
| Q42692514 | How can we reduce the risk of serious infection for patients with systemic lupus erythematosus? |
| Q90157934 | Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy |
| Q36240425 | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence |
| Q41915986 | Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis |
| Q41930905 | Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study |
| Q36906782 | Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients |
| Q38029146 | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects |
| Q39031764 | Hydroxychloroquine in systemic lupus erythematosus (SLE). |
| Q37854742 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy |
| Q55507790 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. |
| Q39172826 | Hydroxychloroquine retinopathy |
| Q58608203 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care |
| Q41913394 | Hydroxychloroquine retinopathy: an emerging problem |
| Q96431036 | Hydroxychloroquine shortage |
| Q34162739 | Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus |
| Q53798136 | Hydroxychloroquine-Induced Erythema Multiforme. |
| Q50435111 | Hydroxychloroquine-induced ototoxicity in a child with systemic lupus erythematosus. |
| Q26782822 | Hydroxychloroquine-related retinal toxicity |
| Q46643929 | Hydroxychloroquine: the cornerstone of lupus therapy |
| Q27302392 | Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents |
| Q38883883 | Immunomodulators in SLE: Clinical evidence and immunologic actions |
| Q55361080 | Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre. |
| Q41917416 | Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study |
| Q36606667 | Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus |
| Q92737341 | Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine |
| Q89842745 | Investigating lupus retention in care to inform interventions for disparities reduction: an observational cohort study |
| Q38362113 | Lupus in Latin-American patients: lessons from the GLADEL cohort. |
| Q37399315 | Lupus nephritis in children - 10 years' experience. |
| Q91575919 | MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study |
| Q37428743 | Management of cardiovascular disease risk in chronic inflammatory disorders |
| Q92625510 | Management strategies and future directions for systemic lupus erythematosus in adults |
| Q36220831 | Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus |
| Q43275139 | Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. |
| Q46901557 | Modern therapy for systemic lupus erythematosus |
| Q89285609 | Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article |
| Q34007922 | New concepts in antimalarial use and mode of action in dermatology |
| Q38026787 | New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. |
| Q90412368 | New therapeutic strategies in systemic lupus erythematosus management |
| Q92625516 | Novel paradigms in systemic lupus erythematosus |
| Q41203763 | On the use and misuse of scalar scores of confounders in design and analysis of observational studies |
| Q64229203 | Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis |
| Q38230699 | Pathogenesis and treatment of atherosclerosis in lupus |
| Q90003782 | Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors |
| Q33555419 | Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort |
| Q38156069 | Pragmatic approaches to therapy for systemic lupus erythematosus |
| Q38600390 | Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. |
| Q33448450 | Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort |
| Q47100353 | Predictors of incident proteinuria among patients with SLE. |
| Q37350893 | Predictors of major infections in systemic lupus erythematosus |
| Q41929732 | Predictors of survival in Chinese patients with lupus nephritis |
| Q37573524 | Premature vascular damage in systemic lupus erythematosus |
| Q37549027 | Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? |
| Q96686028 | Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria |
| Q41941085 | Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival |
| Q30778909 | Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort. |
| Q36234766 | Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort |
| Q52316454 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. |
| Q33455990 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort |
| Q33945242 | Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States |
| Q39997361 | Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels |
| Q37749647 | Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues |
| Q47148511 | Refugee Policy Implications of U.S. Immigration Medical Screenings: A New Era of Inadmissibility on Health-Related Grounds |
| Q33497970 | Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution |
| Q48317028 | Risk of damage and mortality in SLE patients fulfilling the ACR or only the SLICC classification criteria. A 10-year, inception cohort study. |
| Q36551073 | Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. |
| Q36307429 | Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study |
| Q31129756 | Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). |
| Q90177659 | Serum uric acid is associated with damage in patients with systemic lupus erythematosus |
| Q88477714 | Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016 |
| Q40156825 | Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil |
| Q37807147 | Systemic Lupus Erythematosus: Safe and Effective Management in Primary Care |
| Q37033345 | Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention |
| Q39053129 | Systemic lupus erythematosus diagnosis and management |
| Q37921757 | Systemic lupus erythematosus in Hispanics |
| Q50848358 | Systemic lupus erythematosus. |
| Q93193261 | Systemic lupus erythematosus: Diagnosis and clinical management |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
| Q41701045 | Systemic lupus erythematous and clinical outcomes in peritoneal dialysis. |
| Q38709337 | TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells |
| Q48332079 | The Cutaneous Spectrum of Lupus Erythematosus. |
| Q89055903 | The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary |
| Q51135582 | The Sarawak lupus cohort: clinical features and disease patterns of 633 SLE patients in a single tertiary centre from East Malaysia. |
| Q37947108 | The role of antimalarial agents in the treatment of SLE and lupus nephritis |
| Q38897055 | Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus |
| Q37642828 | Thrombosis in systemic lupus erythematosus: risk and protection |
| Q90048328 | Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity |
| Q37137299 | Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort |
| Q38686467 | Towards new avenues in the management of lupus glomerulonephritis |
| Q50726116 | Treatment Algorithms for Patients with Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al. |
| Q37883966 | Treatment of lupus: impact on quality of life |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q52646063 | Type I interferon in rheumatic diseases. |
| Q52659257 | Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. |
| Q35756117 | Update on systemic lupus erythematosus pregnancy |
| Q38011226 | Utilizing registries in systemic lupus erythematosus clinical research |
| Q38388428 | Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. |
| Q28546985 | Violacein Treatment Modulates Acute and Chronic Inflammation through the Suppression of Cytokine Production and Induction of Regulatory T Cells |
| Q38920435 | Why targeted therapies are necessary for systemic lupus erythematosus |
| Q81732655 | [What's new in medicine in 2007?] |
Search more.